A high-stakes fight over how Ohioans get abortion pills and other medications is quietly unfolding at the Statehouse, as a controversial prescription bill starts its run through the Senate.
The proposal would force in-person appointments for certain “high-risk” drugs and has been sent to the Ohio Senate Health Committee after clearing the House last year. Reproductive-rights groups and medical associations warn the measure could be used to curb access to medication abortion, specifically mifepristone and misoprostol, a major concern for patients in parts of the state with few clinics.
House Bill 324, dubbed the Patient Protection Act and introduced by Reps. Adam Mathews (R-Lebanon) and Meredith Craig (R-Smithville), passed the Ohio House by a 60–28 vote and is now before the Senate panel, according to Cleveland Scene. Supporters argue the bill reins in risky mail-order prescriptions, while critics say its metrics could let low-quality or politicized analyses shape access to routine and reproductive care.
What HB 324 Would Do
Under the House version, the bill directs the director of the Ohio Department of Health to publish a list of “dangerous drugs” that cause one or more “severe adverse effects” in more than five percent of users. For drugs that make that list, prescribers would have to conduct an in-person examination, deliver a specific warning to the patient, and schedule a follow-up visit before writing the prescription.
The bill text defines severe adverse effects to include death, infection, or hemorrhaging that requires hospitalization, organ failure, and sepsis. It instructs the health director to base those determinations on whichever data set is larger among insurance claims, patient reports, and any applicable FDA data, according to the legislation posted by the Ohio Legislature.
Backers frame the measure as a patient-safety update for an era of telehealth and mail-order pharmacies. “The Hippocratic Oath is to ‘Do No Harm,’” Rep. Adam Mathews said, and co-sponsor Rep. Meredith Craig told lawmakers the proposal would put “patient safety” ahead of convenience, according to a press release on the Ohio House website.
Medical Community Pushback
Medical organizations and clinicians told House lawmakers the bill lacks scientific guardrails and could let politically motivated reports drive medical decision-making.
The Academy of Medicine of Cleveland & Northern Ohio called the proposal “an attempt to block patients of their right to comprehensive healthcare” and warned that HB 324 opens the door to “bad science” in written testimony to the House Health Committee. Supporters, including the Right to Life Action Coalition of Ohio, submitted proponent testimony urging lawmakers to adopt the safeguards. Ohio Legislature records include opponent testimony, and additional proponent testimony is also posted by the Ohio Legislature.
The Evidence Debate
Supporters of HB 324 have highlighted a recent analysis that relied on insurance claims data and reported a far higher rate of serious complications after medication abortion than clinical trials have typically shown. That report, from the Ethics & Public Policy Center, estimated that roughly 10.9 percent of patients experienced a serious event as per Ethics & Public Policy Center.
Independent researchers and medical journals dispute that methodology and point instead to decades of clinical trials and telehealth studies that find serious complications are rare. For example, a study published in JAMA Network Open on telehealth medication abortion during the COVID-19 pandemic reported low rates of major adverse events. Prescribing information for mifepristone notes that serious infections and heavy bleeding are very uncommon, according to the federal drug label on DailyMed.
Where It Goes From Here
The measure has been referred to the Ohio Senate Health Committee for hearings, but the next hearing had not been scheduled at the time of the most recent report, according to Cleveland Scene. Advocates on both sides are treating it as a major showdown: reproductive-rights groups warn the law could shrink access in low-resource areas and have pledged litigation if it advances, while supporters describe it as a commonsense safety net.
State data show how directly this fight touches Ohio patients. The Ohio Department of Health’s most recent report counted 25,135 induced terminations reported in 2025 and recorded 195 post-abortion complications that year, a small fraction of total procedures, the agency said. The clash over HB 324 is likely to hinge on which kinds of data lawmakers and the health director decide to trust when naming drugs that must be prescribed in person, and the outcome will carry practical consequences for telehealth services, pharmacies, and people seeking care across the state, according to the Ohio Department of Health.
